Lineage Cell Therapeutics: Surges on positive data from eye-disorder treatment study

Lineage Cell Therapeutics

06/02/2020 18:03

** Shares of clinical-stage cell therapy developer  LCTX.A 
rise ~16% to $1.26, a six-month high 
    ** Co says it will accelerate patient enrollment in its
mid-stage study of an eye disorder treatment, after an
independent data safety monitoring board recommended removal of
protocol-mandated treatment stagger
    ** Recommendation came after no unexpected complications
were observed in patients suffering from dry age-related macular
degeneration (dry AMD) upon receiving co's retinal transplant
therapy OpRegan  urn:newsml:reuters.com:*:nBw3hdWjja
    ** Patients receiving OpRegan along with Gyroscope
Therapeutics' Orbit Subretinal Delivery System showed
improvement in vision impairment
    ** AMD affects part of the eye called macula, which is
central part of retina and may lead to blurry vision and even
complete vision loss
    ** Including session's gain, shares rose ~7% in last 12
months

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com ; +91 80 6182 2766))